Dr. Chen reviewed CAR T in RCC: improved safety, challenges in solid tumors; new targets and CRISPR-edited therapies show promising durable responses. Dr. Dizman showed microbiome diversity links to RCC IO outcomes; TOPOSCORE and sMADCAM-1 predict survival; FMT and biotherapeutics show early promise. Dr. Tang highlighted SBRT in RCC: high local control, low toxicity, delays systemic therapy; promising combo trials with immunotherapy underway. Dr. Iravani highlighted 89Zr Girentuximab PET/CT in ccRCC: superior accuracy vs CT/MRI; new tracers and CAIX targeting show promise for imaging and therapy. The panel discussed microbiome, fiber, and CBM588 may predict response; SBRT impacts GFR; biomarkers (VGF, CD70, PSMA, PD-L1) and urine testing aid monitoring.